N@N

Tripp Levy PLLC Announces Investigation of Pharmaceutical Product Development

^{Published on 2011-10-03 17:40:48 - Market Wire}
 

NEW YORK--([ BUSINESS WIRE ])--Tripp Levy PLLC, a leading national securities law firm, announces an investigation into the proposed acquisition of Pharmaceutical Product Development, Inc. (Nasdaq:[ PPDI ]). It was announced that PPDI has entered into a definitive merger agreement under which it will be acquired by affiliates of The Carlyle Group and Hellman & Friedman in an all-cash transaction valued at $3.9 billion, after which PPD will be a private company. Under the terms of the merger agreement, Carlyle and Hellman & Friedman will acquire the outstanding common shares of PPD for $33.25 per share in cash

The investigation concerns, among other things, whether the consideration to be paid to PPDI shareholders is unfair, inadequate, and substantially below the fair or inherent value. Indeed, analysts have projected that the true inherent value of PPDI is $38 per share. The investigation further concerns whether the board of directors of PPDI may have breached their fiduciary duties by not acting in PPDI shareholders' best interests in connection with the sale process of PPDI.

If you own PPDI common stock and you wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact

Tripp Levy PLLC is a national law firm that specializes in mergers & acquisitions, takeover litigation, shareholder rights, and corporate governance matters in state and federal courts throughout the United States. Attorney advertising. Prior results do not guarantee a similar outcome.